289 related articles for article (PubMed ID: 15365568)
21. [Advances on PI3K/Akt/mTOR signalling pathway in malignancies].
Yu BH; Zhou XY
Zhonghua Bing Li Xue Za Zhi; 2005 Oct; 34(10):674-6. PubMed ID: 16536284
[No Abstract] [Full Text] [Related]
22. Targeting the mTOR pathway using deforolimus in cancer therapy.
Mahalingam D; Sankhala K; Mita A; Giles FJ; Mita MM
Future Oncol; 2009 Apr; 5(3):291-303. PubMed ID: 19374536
[TBL] [Abstract][Full Text] [Related]
23. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
Feldman ME; Shokat KM
Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
[TBL] [Abstract][Full Text] [Related]
24. Mammalian target of rapamycin as a therapeutic target in leukemia.
Giles FJ; Albitar M
Curr Mol Med; 2005 Nov; 5(7):653-61. PubMed ID: 16305491
[TBL] [Abstract][Full Text] [Related]
25. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents.
Rao RD; Buckner JC; Sarkaria JN
Curr Cancer Drug Targets; 2004 Dec; 4(8):621-35. PubMed ID: 15578919
[TBL] [Abstract][Full Text] [Related]
26. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.
Mita MM; Mita A; Rowinsky EK
Cancer Biol Ther; 2003; 2(4 Suppl 1):S169-77. PubMed ID: 14508096
[TBL] [Abstract][Full Text] [Related]
27. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
Shi Y; Yan H; Frost P; Gera J; Lichtenstein A
Mol Cancer Ther; 2005 Oct; 4(10):1533-40. PubMed ID: 16227402
[TBL] [Abstract][Full Text] [Related]
28. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.
Wang X; Hawk N; Yue P; Kauh J; Ramalingam SS; Fu H; Khuri FR; Sun SY
Cancer Biol Ther; 2008 Dec; 7(12):1952-8. PubMed ID: 18981735
[TBL] [Abstract][Full Text] [Related]
29. Mammalian target of rapamycin as a target in hematological malignancies.
Kelly KR; Rowe JH; Padmanabhan S; Nawrocki ST; Carew JS
Target Oncol; 2011 Mar; 6(1):53-61. PubMed ID: 21499765
[TBL] [Abstract][Full Text] [Related]
30. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
Gibbons JJ; Abraham RT; Yu K
Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
[TBL] [Abstract][Full Text] [Related]
31. m-TOR inhibitors and their potential role in haematological malignancies.
Calimeri T; Ferreri AJM
Br J Haematol; 2017 Jun; 177(5):684-702. PubMed ID: 28146265
[TBL] [Abstract][Full Text] [Related]
32. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future.
MacKenzie AR; von Mehren M
Expert Rev Anticancer Ther; 2007 Aug; 7(8):1145-54. PubMed ID: 18028023
[TBL] [Abstract][Full Text] [Related]
34. The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas.
Vemulapalli S; Mita A; Alvarado Y; Sankhala K; Mita M
Target Oncol; 2011 Mar; 6(1):29-39. PubMed ID: 21533543
[TBL] [Abstract][Full Text] [Related]
35. NCCN Task Force Report: mTOR inhibition in solid tumors.
Figlin RA; Brown E; Armstrong AJ; Akerley W; Benson AB; Burstein HJ; Ettinger DS; Febbo PG; Fury MG; Hudes GR; Kies MS; Kwak EL; Morgan RJ; Mortimer J; Reckamp K; Venook AP; Worden F; Yen Y
J Natl Compr Canc Netw; 2008 Sep; 6 Suppl 5():S1-20; quiz S21-2. PubMed ID: 18926092
[TBL] [Abstract][Full Text] [Related]
36. Updates of mTOR inhibitors.
Zhou H; Luo Y; Huang S
Anticancer Agents Med Chem; 2010 Sep; 10(7):571-81. PubMed ID: 20812900
[TBL] [Abstract][Full Text] [Related]
37. The biology behind mTOR inhibition in sarcoma.
Wan X; Helman LJ
Oncologist; 2007 Aug; 12(8):1007-18. PubMed ID: 17766661
[TBL] [Abstract][Full Text] [Related]
38. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development.
Mita M; Sankhala K; Abdel-Karim I; Mita A; Giles F
Expert Opin Investig Drugs; 2008 Dec; 17(12):1947-54. PubMed ID: 19012509
[TBL] [Abstract][Full Text] [Related]
39. Mammalian target of rapamycin: a central node of complex signaling cascades.
Dobashi Y; Watanabe Y; Miwa C; Suzuki S; Koyama S
Int J Clin Exp Pathol; 2011 Jun; 4(5):476-95. PubMed ID: 21738819
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of mTOR inhibitor resistance in cancer therapy.
Carew JS; Kelly KR; Nawrocki ST
Target Oncol; 2011 Mar; 6(1):17-27. PubMed ID: 21547705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]